about
Zika virus in saliva—New challenges for prevention of human to human transmissionPersistent detection of Zika virus RNA in semen for six months after symptom onset in a traveller returning from Haiti to Italy, February 2016HIV-1 drug resistance in recently HIV-infected pregnant mother's naïve to antiretroviral therapy in Dodoma urban, Tanzania.Inconsistent condom use among HIV-positive women in the "Treatment as Prevention Era": data from the Italian DIDI study.Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection.Pregnancy outcomes in women with advanced HIV infection in Italy.Genotypic resistance tests for the management of the patient failing highly active antiretroviral therapy: the resistance pattern in different biological compartments.Brief Report: Consequences of Presentation With Advanced HIV Disease in Pregnancy: Data From a National Study in Italy.HIV pharmacogenetics in clinical practice: recent achievements and future challenges.Travel-Associated Zika Virus Disease.Monophyletic HIV type 1 CRF02-AG in a nosocomial outbreak in Benghazi, Libya.Zika virus and microcephaly: is the correlation causal or coincidental?Zika virus and microcephaly: is the correlation, causal or coincidental?The HIV-1 reverse transcriptase polymorphism A98S improves the response to tenofovir disoproxil fumarate+emtricitabine-containing HAART both in vivo and in vitro.Variable prediction of antiretroviral treatment outcome by different systems for interpreting genotypic human immunodeficiency virus type 1 drug resistance.Successful prevention of HIV mother-to-child transmission with dolutegravir-based combination antiretroviral therapy in a vertically infected pregnant woman with multiclass highly drug-resistant HIV-1.Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study.Pregnancy outcomes in HIV-infected women of advanced maternal age.Persistence of ZIKV-RNA in the cellular fraction of semen is accompanied by a surrogate-marker of viral replication. Diagnostic implications for sexual transmission.Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.Reduction of HIV-1 viral load in saliva by indinavir-containing antiretroviral regimen.Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients.Q151M-mediated multinucleoside resistance: prevalence, risk factors, and response to salvage therapy.Safe conception for human immunodeficiency virus-discordant couples: the preexposure prophylaxis for conception alternative.Role of NEDD8 in HIV-associated lipodystrophy.Lipodystrophy is associated with a low rate of treatment failure in HIV-positive patients switched to atazanavir.Glucose plasma levels and pregnancy outcomes in women with HIV.Drug-resistant mutants of HIV-1 in patients exhibiting increasing CD4 cell count despite virological failure of highly active antiretroviral therapy.Clinical management of women with listeriosis risk during pregnancy: a review of national guidelines.Plasma HIV RNA Decline and Emergence of Drug Resistance Mutations among Patients with Multiple Virologic Failures Receiving Resistance Testing-Guided HAARTDynamics of viral load rebound in plasma and semen after stopping effective antiretroviral therapy
P50
Q24261395-C3F95204-1504-4C70-A93A-C3D8BF736FF2Q26261633-EE0BE12E-4556-4F45-9941-C49EA9544489Q34993070-6D4C5CE7-BFEB-41FF-938E-0CA94E7AB5B0Q35019858-EBAECBA0-8246-404E-9002-0EACB9ED1EC4Q35315818-EDC48461-D5FB-47DE-ADEE-8B9E9976B318Q35445035-F03B631A-1CD0-4A19-9C32-877AE70AE376Q35682447-21915411-199E-4DCF-A0AF-9A08AC945D1CQ35742484-662CDAC9-BF1C-4E0E-92DF-556EEAC069E3Q37320235-C9707B15-C6BD-45A3-90F8-836EB91A9884Q38158698-F12DAEC8-BEE3-48B2-90BC-C8A7F521766AQ39562755-4F002E70-03A6-4506-B58D-C5F1EFE7CBFFQ39753287-4033B11D-D490-4BCE-8241-0B2859C48514Q40060853-BEC6DB83-0B40-4D57-8898-809635736F61Q40573390-73F6A926-85E2-44A4-9736-3E4F074E22C1Q40583081-A7859830-1FCA-4910-9F16-C5FF67190C5FQ40998601-BF25F586-178E-4429-ABB9-74E0D491B234Q42235471-E8D7552A-3DA2-42D6-A4AE-003BC08AE0F0Q42255965-834D1BFC-5840-46B5-815D-C034321BBC3CQ43046734-A5EE41D8-8E3E-400A-987F-BA5A61C5473BQ43280880-B9DDCE5A-5727-4F43-90AC-74EBED5BCC8CQ43880778-5AD50F24-3A94-44DB-AF67-2D8B3373B96EQ44156443-4E10A6DF-5E0C-49C2-A68D-47CA26ADA1F9Q44731174-F0342DA9-FAE0-4C03-BAF6-D1382D016BFFQ45350004-749F470A-2025-43CE-9E11-BBAC875E257AQ46073438-A1B745B4-16A1-4720-A4F3-BBE2FCF7128AQ46455678-AABC36C8-2A2C-4C5D-AA4B-2F5B292D5459Q51363612-6552D306-B288-4700-A313-75A7C1E7BEEAQ53988646-C95CD344-1265-4447-8931-B68793A01B9BQ54301676-152A05A5-B261-4CDB-A901-44CA96185E7FQ56790281-7733C7B9-D63D-4348-B267-F12C81518D81Q56790394-02E3F41A-1BF3-4E39-9DAA-353255738408
P50
name
Giuseppina Liuzzi
@ast
Giuseppina Liuzzi
@en
Giuseppina Liuzzi
@nl
type
label
Giuseppina Liuzzi
@ast
Giuseppina Liuzzi
@en
Giuseppina Liuzzi
@nl
prefLabel
Giuseppina Liuzzi
@ast
Giuseppina Liuzzi
@en
Giuseppina Liuzzi
@nl